New triple therapy aims to halt rare, aggressive melanoma
NCT ID NCT07236528
First seen Nov 19, 2025 · Last updated May 15, 2026 · Updated 20 times
Summary
This study tests a combination of two drugs (carilizumab and apatinib mesylate) plus radiation therapy as a first treatment for advanced mucosal melanoma, a rare and aggressive skin cancer. About 30 adults who have not had prior systemic treatment will receive this triple therapy. The goal is to see if it can control the disease and improve survival, though ongoing management is expected.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MUCOSAL MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.